A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis
Volunteers
Health Professionals
What is the purpose of this trial?
Data from a completed phase 2/3 trial, MOL-PAP-002, suggested that molgramostim, an inhaled form of the recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF), improves lung pathology, pathophysiology, and health status in subjects with aPAP in a dose-frequency dependent fashion. The present confirmatory phase 3 trial will be conducted to further investigate the efficacy and safety of molgramostim in subjects with aPAP.
- Trial withSavara Inc.
- Ages18 years and older
- GenderBoth
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Last Updated01/30/2024
- Study HIC#2000029603